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Background: Newly diagnosed patients without anti-tuberculosis (TB) treatment histories have not often under-
gone drug susceptibility testing (DST), but have received the standard treatment regimen without information
about their DST profiles in many countries with inadequate resources.
Methods: We collected 346 clinical isolates from previously untreated patients with smear-positive active TB in
Hanoi, the capital of Vietnam. Of these, 339 were tested for susceptibility to four first-line anti-TB drugs, including
isoniazid (INH), rifampicin (RMP), streptomycin (SM), and ethambutol (EMB), using the proportion method. A pyrazi-
namidase (PZase) test was used to assess pyrazinamide (PZA) resistance. Results of the culture-based drug suscepti-
bility tests were confirmed by those from reverse hybridization-based line probe assays (LiPAs) that detected
mutations associated with RMP, INH, PZA, and fluoroquinolone (FQ) resistance. To investigate a diversity of these
strains, IS6110-probed restriction fragment length polymorphisms (RFLPs) were analyzed. Nucleotide sequences for
furA-katG and fabG1-inhA operons, transcription units responsible for INH resistance, were also determined.
Results: Of the isolates tested, 127 (37.5%) were resistant to at least one of the four drugs, which included 93
(27.4%) isolates that were resistant to INH. RFLP analysis identified four clusters defined by similarity of the band
patterns, which accounted for 46.1% of the tested isolates. Among the clustered isolates, 37.7% were resistant to
INH, most of which (85.4%) carried a g944c mutation, which causes an S315T amino acid substitution, in the katG
gene.
Conclusions: Our results suggest that drug-resistant strains, particularly those with INH resistance characterized by
a single mutation, S315T, are spreading in Hanoi, Vietnam. When RMP resistance is combined with this setting, pa-
tients are not easily cured by conventional short-term treatment. We will need to carefully monitor these trends
and search for the origins and transmission routes of these strains.
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The drug susceptibility profiles of clinically isolated
Mycobacterium tuberculosis (MTB) strains, particularly
those from previously untreated patients, have not been
included in clinical practice in many countries with in-
adequate resources. A single standard anti-tuberculosis
(TB) treatment without information regarding drug sus-
ceptibility is prone to failure or relapse, as initial drug
resistance increases the chance of acquiring additional
drug resistance [1].
Molecular fingerprinting of MTB strains has been used
extensively and is crucial for elucidating the transmis-
sion routes of drug-resistant TB [2,3]. A rapidly develop-
ing large city is often accompanied by overcrowding and
a floating population, and it is often not easy to identify
the epidemiological link between TB cases. Nevertheless,
the molecular epidemiological techniques are useful for
providing insights into the spread patterns of MTB on
site and can thus aid in enhancing TB control activities
in the entire city.
Vietnam is a Southeast Asian country stretching over
1,800 km from north to south. It is one of 22 high-burden
countries worldwide, and its TB prevalence remains high
(323 per 100,000 in 2011) [4]. Vietnam reported an inci-
dence of 2.7% multi-drug resistant-TB among new cases
in a 2006 survey (95% confidence interval: 2.0–3.6) [5].
The northern and southern regions of Vietnam have
also been under different health policies for more than
20 years. It remains unclear whether entire profiles of
MTB isolates obtained in one area are equally useful
throughout the country. An earlier report [6] suggested
differences in genotypes and drug susceptibility patterns
between isolates obtained in distant regions of Vietnam.
Although the status of primary drug resistance has
been reported in some areas of Vietnam [7-9], molecular
biological approaches to this issue have not yet been
completely exploited. Thus, we analyzed the profiles of
drug susceptibility testing (DST), drug resistance genes,
and fingerprint patterns of MTB isolates obtained from
339 previously untreated patients with smear-positive
active TB in Hanoi, the capital of Vietnam.
Methods
Ethics statement
A written informed consent was obtained from each par-
ticipant. The study was approved by ethical committees
of the Ministry of Health, Vietnam and National Center
for Global Health and Medicine, Japan.
Clinical isolates from acid-fast bacilli (AFB)-positive
sputum
Clinical isolates were consecutively collected from previ-
ously untreated patients with AFB-positive active TB in
Hanoi city between August 2007 and August 2008. Atleast two sputum specimens were collected from each
patient; one was for a smear test and the other was used
for culture in the Department of Microbiology of the
Hanoi Lung Hospital. Specimens were decontaminated
and homogenized with 0.5% NALC–2% NaOH and sub-
sequently inoculated on Löwenstein–Jensen media. MTB
isolates were transferred to the Molecular Biology La-
boratory of the National Lung Hospital and subjected to
MTB identification using niacin and nitrate tests, DST,
and other molecular epidemiological tests.
Drug susceptibility testing (DST)
DST was performed using the proportion method based
on World Health Organization (WHO) guidelines [10].
The test medium contained rifampicin (RMP; 40 μg/mL),
isoniazid (INH; 0.2 μg/mL and 1.0 μg/mL), ethambutol
(EMB; 2.0 μg/mL), and streptomycin (SM; 4.0 μg/mL).
Drug resistance was defined as ≥1% colony growth com-
pared with a drug-free control of Löwenstein–Jensen
medium.
Pyrazinamidase (PZase) assay
PZase activity was determined by Wayne’s method with
minor modifications [11,12]. As a positive control, we
used the MTB H37Rv strain that is susceptible to pyrazi-
namide (PZA) and is positive for PZase. As a negative
control, we used the M. bovis BCG strain that is resist-
ant to PZA and is negative for PZase.
Isolation of genomic DNA
Genomic DNA from MTB was extracted using the ori-
ginal method described [13], with slight modifications
[14]. Approximately 400 μl of a bacterial suspension in
TE buffer was heated at 80°C for 20 min to kill bacteria.
First, 50 μl of lysozyme (10 mg/ml) was added followed
by incubation at 37°C for 1 h. Subsequently, 75 μl of
SDS/proteinase K was gently mixed followed by incuba-
tion at 65°C for 10 min. In addition, 100 μl of 5-M NaCl
and 100 μl of CTAB/NaCl solution were thoroughly
mixed and incubated for 10 min at 65°C. An equal volume
(approximately 750 μl) of chloroform/isoamylalcohol was
added, and the mixture was centrifuged for 5 min at
12,000× g. The aqueous supernatant was carefully trans-
ferred to another tube. Total DNA was precipitated in iso-
propanol and was dissolved in 0.1× TE buffer.
Line probe assays (LiPAs)
Reverse hybridization-based LiPAs were used to confirm
the results of DST and to detect mutations associated
with resistance to RMP [15], INH [16], PZA [12], and
fluoroquinolone (FQ) [17]. To detect mutations associ-
ated with RMP resistance, 5 oligonucleotide probes were
used to hybridize to wild-type sequences and 4 probes to
mutation sequences of the rpoB gene. For INH resistance,
Table 1 Drug susceptibility profiles of MTB isolates from
previously-untreated patients
Patterns n % (95% CI)
Sensitive with all drugs 212 62.5 (57.3 - 67.5)
Any resistance Subtotal 127 37.5 (32.5 - 42.7)
INH 93 27.4 (23.0 - 32.4)
RMP 19 5.6 (3.6 - 8.6)
SM 96 28.3 (23.8 - 33.3)
EMB 11 3.2 (1.8 - 5.7)
MDR 17 5.0 (3.2 - 7.9)
N = 339 isolates.
INH concentration (0.2 μg/mL).
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tions in the regions of katG (35 probes), furA (2 probes),
fabG1-inhA promoter (2 probes), and fabG1 (2 probes).
The details and performances of these tests have been re-
ported in the references described above [12,15-17].
Restriction fragment length polymorphism (RFLP)
Experimental procedures for bacterial growth, DNA ex-
traction, DNA digestion with PvuII (Takara Bio Inc.
Otsu, Japan), electrophoresis on a 1% agarose gel, and
Southern blotting and membrane hybridization with a
peroxidase-labeled 245-bp IS6110 probe were performed
using standardized methods [18] with slight modifica-
tions [14]. The hybridized probe was visualized with an
ECL detection system (Amersham Biosciences). Finger-
printing images were analyzed with Fingerprinting™ II
software (Bio-Rad Laboratories, Inc., Hercules, CA), and
percent similarity among the isolates was determined ac-
cording to the supplier’s instructions. To classify strains
into the same family on the basis of their genotyping
profiles, a similarity index of 70%, slightly more strin-
gent than 65% used in a previous report [19] was chosen
in this study. Normalization was performed using mo-
lecular weight standards and the IS6110-fingerprinting
patterns of two isolates run on each gel. Isolates with
fewer than five IS6110 copies were excluded from the
cluster analysis.
DNA sequencing of INH resistance-related genes
The furA-katG operon and its upstream region were
amplified by PCR using the specific primers and conditions
described previously [16]. The primers used were −129furA
(5′-GCTCATCGGAACATACGAAG-3′) and katG +50
(5′-GTGCTGCGGCGGGTTGTGGTTGATCGGCGG-
3′). The fabG1-inhA operon and the upstream region of
the fabG1-inhAoperon were also amplified using previ-
ously reported primers [16]: −200fabG1 (5′-TTCGTA
GGGCGTCAATACAC-3′) and inhA +40 (5′-CCGAA
CGACAGCAGCAGGAC-3′). PCR products were used
as templates for direct DNA sequencing. To detect
mutations, DNA sequences were compared with those
of H37Rv using Genetyx-Mac, version 14.0.2 (Genetyx
Corporation, Tokyo, Japan).
Statistical analysis
Chi-square tests were used to compare proportions be-
tween two groups. Kappa statistics were used to determine
the agreement between two tests. The following guidelines
were used to interpret kappa coefficients: <0, poor agree-
ment; 0–0.20, slight; 0.21–0.40, fair; 0.41–0.60, moderate;
0.61–0.80, good; and 0.81–1.00, very good. P values <0.05
were considered statistically significant, unless otherwise
noted. The Bonferroni correction was used when compar-
ing the results for multiple drugs. JMP version 9.0.0 (SASInstitute, Inc., Cary, NC, USA) statistics software was used
for analysis.
Results
Clinical isolates from AFB-positive sputum
Clinical isolates were collected from 346 consecutive
previously-untreated patients with AFB-positive active
TB in Hanoi, Vietnam. Of these patients, 270 (78.0%)
were male, and their median age was 38 years (range:
17–84 years). Coinfection with HIV was found in 31 pa-
tients (9.0%).
Drug susceptibility profiles of MTB isolates
Sputum samples from 346 smear-positive patients were
cultured, from which 339 MTB isolates (98.0%) were
obtained. DST information for seven patients was not
available. Among these, 127 (37.5%) were resistant to at
least one of the four drugs tested; 93 (27.4%), 19 (5.6%),
96 (28.3%), and 11 (3.2%) isolates were resistant to INH,
RMP, SM, and EMB, respectively; and 17 (5.0%) were
multidrug-resistant (MDR) strains (Table 1). The PZase
assay revealed that 8 (2.4%) of the 339 isolates were
negative for PZase and were considered to be resistant
to PZA (data not shown).
Eighty-eight INH-sensitive and 64 INH-resistant strains
were randomly selected. LiPAs for RMP and INH were
performed to confirm consistency with the results of
culture-based DST and to identify profiles of genetic mu-
tations associated with resistance to these drugs. Agree-
ment between LiPAs and conventional DST was good or
very good (kappa = 0.80 for RMP and kappa = 0.84 for
INH 0.2 μg/mL; table not shown).
Mutations for RMP included rpoB:H526D, H526Y,
S526D, and S531L. Only 11 isolates had one of these
mutations, and 4 undefined RMP mutations were also
observed in our study.
Mutations for INH were mostly katG:S315T (data
not shown). This was more widely confirmed by sub-
sequent DNA sequencing around the katG and inh
genes (Additional file 1). LiPA for PZA was compared
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was moderately high (kappa = 0.55; table not shown).
LiPA for FQ identified only 1 mutated strain carrying
gyrA:A90V.
IS6110-probed RFLP and drug susceptibility
Sufficient DNA was extracted from 317 of the 339 iso-
lates. Their IS6110-probed fingerprinting patterns are
shown in Figure 1. Four clusters were identified when
defined by >70% similarity in their RFLP patterns. TheseFigure 1 IS6110-probed fingerprinting patterns (N = 317).clusters accounted for 146 (46.1%) of the total isolates:
57 (18.0%) in cluster I; 70 (22.1%) in cluster II; 12 (3.8%)
in cluster III; and 7 (2.2%) in cluster IV. Each cluster
consisted of isolates collected from at least three districts
in the city of Hanoi (data not shown).
Within these four clusters, 55 and 49 (37.7% and
33.6%) of the isolates were resistant to INH at 0.2 μg/mL
and 1.0 μg/mL, respectively; these proportions were
significantly higher than the 19.9% and 17.0% among
the non-clustered isolates (P = 0.0004 and P = 0.0006,
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and IV, the majority of the isolates were highly resist-
ant to INH at 1.0 μg/mL (Additional file 1: Table S1).
Although the proportions of isolates in these clusters
that were resistant to RMP and other drugs also
tended to be higher than those of non-clustered iso-
lates, these differences were not significant, based on
multiple comparisons statistical testing (Table 2). In
addition, there were no significant associations be-
tween the clusters and specific rpoB mutations (data
not shown).
Gene mutations responsible for INH resistance
Among all the INH-resistant isolates noted above, possible
mutations within the furA-katG operon, the fabG1-inhA
operon, and their upstream regions were investigated by
PCR-based nucleotide sequencing (Additional file 1:
Table S1).
Of 89 INH (0.2 μg/mL)-resistant isolates, 76 (85.4%)
carried a g944c mutation (AGC to ACC) that caused an
S315T amino acid substitution in the katG gene and 70
(92.1%) of the isolates that carried the g944c mutation
were highly resistant to INH at 1.0 μg/mL. Furthermore,
g204c mutations in the furA operon were detected in
13.6% of all the isolates and were frequently accompan-
ied by the g944c mutation in the katG gene, although
this variant itself was not directly associated with culture-
based INH resistance (P = 0.072; table not shown). In the
upstream region of the fabG1-inhA operon, c-15t was ob-
served in 7 isolates, and minor variations with <1% were
observed within the fabG1-inhA operon. The combination
of a g944c mutation in the katG gene with c-15t in the
inhA promoter was observed only in 1 isolate.
Discussion
We investigated the drug susceptibility profiles of clin-
ical isolates obtained from previously untreated patients
with active pulmonary TB in Hanoi, the northern largest
city in Vietnam, and found that a quarter of these iso-
lates were highly resistant to INH, most of which had aTable 2 The relationship between drug resistance and
clustering of the clinical isolates in Hanoi
Resistant to MTB isolates P value*
Clustered Non-clustered
N = 146 N = 171
INH (0.2 μg/mL) 55 (37.7%) 34 (19.9%) 0.0004
INH (1.0 μg/mL) 49 (33.6%) 29 (17.0%) 0.0006
RMP 13 (8.9%) 6 (3.5%) 0.0437
SM 49 (33.6%) 41 (24.0%) 0.0592
EMB 7 (4.8%) 4 (2.3%) 0.2338
*P values by chi-square test. P < 0.01 was regarded as statistically significant
after considering multiple comparisons.single S315T mutation in the katG gene. These isolates
with primary resistance to INH were enriched in the
clusters identified by RFLP. They probably originated
from a few genetically related clones and were recently
transmitted into and spread within this area of Vietnam.
Among the isolates with resistance to the first-line
drugs tested in this study, a high proportion of primary
INH resistance (27.4%) was rather characteristic. This
resistance level was higher than the average (19.1%) ob-
tained during a 2006 nation-wide survey [5]. Such a high
level of primary resistance is a serious concern because
INH is a key drug by which newly diagnosed TB patients
can be successfully treated. In Vietnam, culture-based
DST has not yet been routinely performed for previously
untreated patients, and the standard regimen for these
patients remained 2S(E)HRZ/6HE for a long time [20].
In the years when RMP-based treatment was not easily
accomplished during the maintenance phase in areas
with inadequate resources, this regimen had certain
significance and was thus endorsed by the WHO until
recently [21].
However, when DST results are unknown and the above
standard regimen is used for INH-resistant TB, treatment
during the maintenance phase is no more than EMB
monotherapy, which could increase the chances of failure,
early relapse, and additional drug resistance [21,22]. Pre-
scribing 2RHEZ/4RHE, a regimen that includes 6 months
of RMP, has also been recently approved by the national
TB program in Vietnam. Because treatment outcomes are
largely affected by locale-specific factors, including patient
adherence to the regimen and drug resistance profiles of
the prevailing strains, further studies will be needed to
confirm the optimal regimens in Vietnam [23].
To reduce the likelihood of failure, relapse, and add-
itional acquired drug resistance in major cities, updating
clinical laboratories for DST is an urgent need [21]. In
addition to DST for first-line drugs, detecting resistance
to second-line drugs, including FQ, has also become im-
portant recently [24], although the proportion appeared
to be low (<1%) in our study. Even in a resource-poor set-
ting, as per timely DST results, health care staff should
treat and intensively follow up those patients with drug-
resistant TB with the aim of complete cure in most of
these cases and to prevent further spread of MDR-TB and
generation of extensively drug-resistant TB.
Genetic analysis of our MTB isolates demonstrated
that >85% of the INH resistance (92% with high-level re-
sistance) was caused by a S315T mutation in the katG
gene. The predominance of this mutation in INH resist-
ance has been observed in most of the areas with high
TB prevalence, although the proportion (85%) in our
study was relatively high compared with what was re-
ported in other studies [25-27]. Continuous use of INH
may cause additional mutations and induce higher levels
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at an early phase is important to break this chain of acquir-
ing additional resistance. Predominance of the S315T mu-
tation is potentially advantageous for providing molecular
DST in a resource-limited setting because it might entice
manufacturers to develop a simplified, maintenance-free
genetic test specialized for detecting the relevant mutations
at a reasonably low cost [29].
RFLP analysis demonstrated that primary resistance to
INH was more often observed in clustered isolates than
in non-clustered isolates. Resistance to other drugs also
appeared to be associated with these clustered isolates,
although the tendencies were not as clear as that for
INH. This indicates that expansion of INH-resistant iso-
lates presumably originated from a few genetically re-
lated clones and that they were transmitted into the city
of Hanoi and they spread widely within a relatively short
period. Rapid expansion of genetically related strains
may also explain why a single INH-resistant mutation,
S315T, was predominantly detected in this area.
In our study, other genotype data for these clinical iso-
lates were not available. However, in Vietnam, particularly
in the southern region, two families of strains, designated
the Beijing genotype and a presumably indigenous East-
African Indian (EAI) genotype, are known to be predom-
inant [30]. According to the literature, strains with ≥15
IS6110 copies may indicate typical Beijing strains [31],
whereas most of the EAI strains in Vietnam have <5 cop-
ies [30]. The copy numbers and RFLP pattern profiles in
large cluster II in our study were definitely consistent with
those of Beijing strains, whereas approximately one-fourth
of the isolates had a few copies that are observed in EAI.
IS6110 copy numbers in other clusters were those be-
tween these two families. An earlier study demonstrated
that copy numbers of northern strains in Vietnam were
relatively smaller than those of southern strains in which
typical Beijing genotypes are frequently observed [6]. We
will need to further characterize the strains originating
from the Hanoi area in future genotypic studies.
Our study had some limitations. The isolates analyzed
in this study were collected from sputum smear-positive
patients who visited TB clinics. Therefore, we may have
only extracted features of MTB isolates from moderate
to severe pulmonary TB cases. Nevertheless, understand-
ing the current status of highly transmissible smear-
positive TB is a priority for TB control because Vietnam is
one of the high TB burden countries.
Conclusions
High levels of primary resistance to INH and emerging
RMP resistance may be closely related to the problems
of a rapidly developing city, such as the distribution of
young workers with low incomes, undernutrition, poor
hygiene, and crowding in a densely populated urban areawith a floating population. Private acquisition and in-
appropriate use of anti-TB drugs through unofficial dis-
tribution routes are also difficult to manage in a large
city such as Hanoi. It will be necessary to curb the trans-
mission of drug-resistant MTB by considering effective
counter measures. We will need to carefully monitor
these trends further and search for the origins and trans-
mission routes of these Southeast Asian MTB strains.
Additional file
Additional file 1: Table S1. Drug susceptibility testing and DNA
sequencing of M. tuberculosis clinical isolates (N = 317).
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